Hypothesis

IF patients with rheumatoid arthritis (RA) who harbor DNMT3A loss-of-function CHIP mutations (VAF ≥2%) in their hematopoietic stem cells are compared to age- and disease-matched RA patients without CHIP,

THEN CHIP-positive RA patients will exhibit:

1. Accelerated epigenetic aging (≥5-year GrimAge acceleration vs CHIP-negative controls)
2. Elevated synovial tissue senescent cell burden (p16^INK4a+ and SA-β-gal+ macrophages increased ≥2-fold)
3. Resistance to conventional DMARD therapy (failure to achieve DAS28-CRP <3.2 by 6 months at ≥1.5x the rate of CHIP-negative patients)
4. Higher circulating SASP cytokine signature (IL-6, MMP-3, CXCL9, GDF-15 composite z-score ≥1 SD above CHIP-negative)

Mechanistic Rationale

DNMT3A loss-of-function mutations cause global CpG hypomethylation in myeloid-lineage cells, particularly monocytes/macrophages. This produces a dual pathological cascade:

1. Epigenetic derepression of pro-inflammatory loci: Hypomethylation at NF-κB target gene promoters (TNF, IL1B, IL6) in DNMT3A-mutant macrophages creates a constitutively primed inflammatory state that synergizes with RA-specific autoimmune activation. This is distinct from normal inflammaging — it is clonally driven and self-amplifying as mutant clones expand with age.

2. Paracrine senescence induction: DNMT3A-mutant macrophages infiltrating synovium secrete excess IL-1α and TNF, driving bystander senescence in fibroblast-like synoviocytes (FLS) via the p53-p21 pathway. Senescent FLS then produce a SASP that further recruits CHIP-derived inflammatory monocytes, creating a feed-forward loop between clonal hematopoiesis and tissue-level senescence.

3. Epigenetic clock acceleration: The systemic inflammatory burden from CHIP-mutant myeloid cells accelerates DNAm-based aging clocks (particularly GrimAge, which weights inflammatory protein surrogates) independently of chronological age, positioning CHIP as a biological age amplifier in the autoimmune context.

Testable Predictions

• Cross-sectional: In a biobanked RA cohort (n≥500) with available WES/targeted sequencing (DNMT3A, TET2, ASXL1) and methylation arrays (EPIC v2), CHIP-positive patients will show GrimAge acceleration >5 years vs CHIP-negative after adjusting for chronological age, sex, smoking, and disease duration.
• Synovial biopsy sub-study: Paired blood + synovial tissue from CHIP+ vs CHIP- RA patients (n≥30) will show that p16+ macrophages in synovium carry the same DNMT3A mutation (confirmed by single-cell genotyping), establishing clonal origin of tissue senescence.
• Therapeutic implication: Senolytic adjuvant therapy (dasatinib + quercetin) in CHIP-positive RA non-responders should reduce SASP biomarkers and improve DAS28 response vs DMARD-only controls.

Limitations

• CHIP prevalence in RA cohorts is estimated at 15-25% (age >60), requiring large cohorts for adequate power
• Confounding by age (CHIP increases with age, as does RA severity) requires careful matching or Mendelian randomization
• Synovial biopsy sub-study is invasive and may have selection bias toward more severe disease
• GrimAge acceleration may partly reflect RA-driven inflammation rather than CHIP specifically — multi-clock analysis (Horvath, PhenoAge, DunedinPACE) needed for triangulation

Significance

This hypothesis bridges geroscience and autoimmune rheumatology by proposing that clonal hematopoiesis is a previously unrecognized driver of accelerated biological aging in RA, operating through a macrophage-senescence feed-forward loop. If confirmed, CHIP genotyping could stratify RA patients for senolytic-augmented treatment strategies, representing a precision geroscience approach to rheumatic disease.